Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor

Ang Li; Nathaniel B Rieveschl; Felipe F Conti; Fabiana Q Silva; Jonathan E Sears; Sunil Srivastava; Justis P Ehlers; Andrew P Schachat; Amy S Babiuch; Peter K Kaiser; Daniel F Martin; Rishi P Singh

doi:10.1016/j.oret.2017.10.010

Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor

Ophthalmol Retina. 2018 Jun;2(6):550-557. doi: 10.1016/j.oret.2017.10.010. Epub 2017 Dec 19.

Affiliations

¹ Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
² Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: SINGHR@ccf.org.

PMID: 31047607
DOI: 10.1016/j.oret.2017.10.010

Abstract

Purpose: Although intravitreal anti-vascular endothelial growth factor (VEGF) injection has become the mainstay treatment for neovascular age-related macular degeneration (nAMD), emerging studies suggest that anti-VEGF may be correlated with the development of macular atrophy (MA) in chronic therapy. The purpose of the current study is to determine the prevalence and progression of MA in nAMD treated with chronic anti-VEGF in a routine clinical practice.

Design: Retrospective cohort.

Participants: Patients with nAMD who were previously treatment-naïve and treated with anti-VEGF at the Cole Eye Institute for at least 4 years.

Methods: This is chart review on anti-VEGF treated patients with nAMD with baseline and yearly follow-up spectral domain-OCT for at least 4 years. Retinal pigment epithelium subillumination analysis was used to automate identification of atrophy. Segmentation errors were manually corrected by 4 expert raters using a standardized grading protocol to quantify MA size. Patient baseline characteristics and treatment course were analyzed to identify predictive factors for the development of MA.

Main outcome measures: MA growth rate and prevalence in cohorts with and without baseline atrophy.

Results: A total of 79 eyes from 66 patients (79.8±7.4 years, 63% were female) with nAMD and 4 years of follow-up with anti-VEGF injections were identified. The mean baseline visual acuity was 0.48±0.25 logarithm of the minimum angle of resolution (20/60 Snellen equivalent), and the mean final visual acuity was 0.48±0.49 logarithm of the minimum angle of resolution (20/44 Snellen equivalent, P = 0.23). The average number of injections was 19.8±9.8. MA was observed in 12.7% of eyes at baseline with an average annual growth rate of 0.7±0.5 mm². In eyes without baseline MA, atrophy developed in 53.6% eyes by year 4 with a growth rate of 0.2±0.4 mm² per year. Multiple linear regression analysis revealed that the progression of MA was positively correlated with age (R = 0.02, P = 0.009).

Conclusions: More than half of patients with nAMD treated with anti-VEGF injections for 4 years developed new MA. Atrophy progression was most strongly correlated with age, which suggests that baseline disease characteristics may be more predictive of MA progression than cumulative anti-VEGF treatment.